Shares of Glenmark Prescription drugs Ltd have been buying and selling within the purple and 1% decrease on Thursday, 27 February, regardless of the corporate’s US-based subsidiary asserting launching its epinephrine injection USP, a drugs used to deal with extreme allergic responses.
An injection comprising 10 mg/10 mL (1 mg/mL) has been launched in a multiple-dose container.
Glenmark mentioned in a inventory change submitting that the newly launched drug is bioequivalent to the reference-listed drug made by BPI Labs, LLC, and therapeutically equal.
This launch offers Glenmark a 180-day FD&C Act Aggressive Generic Remedy (CGT) exclusivity.
Epinephrine is used to deal with extreme allergic reactions and sudden bronchial asthma episodes. Moreover, it will probably assist regulate low blood stress and decrease coronary heart price. By avoiding allergic reactions, it reduces signs together with respiratory points and swelling of the face, lips, and throat.
In response to IQVIA gross sales statistics, the Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) market as an entire earned gross sales of round $42.7 million for the 12 months that resulted in December 2024.
With Glenmark’s entry into this business, healthcare organizations ought to have the ability to substitute the current reference product with a high-quality, cost-effective different.
Marc Kikuchi, President & Enterprise Head of North America, mentioned, “We’re excited to announce the launch of epinephrine injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose Vial, rising our portfolio of merchandise throughout the institutional channel whereas additionally strengthening our dedication to bringing high-quality and inexpensive alternate options to sufferers.”
Worldwide pharmaceutical firm Glenmark is a significant participant within the over-the-counter (OTC), generic, and branded sectors and is dedicated to analysis. Therapeutic areas like dermatology, respiratory care, and oncology are the corporate’s areas of experience.
With 11 wonderful manufacturing amenities dispersed over 4 continents and actions in additional than 80 international locations, Glenmark continues to broaden its presence by growing revolutionary and inexpensive pharmaceutical options.
At 1:39 pm, the shares of Glenmark Pharma have been buying and selling 1.53% decrease at Rs 1,296.15 on NSE.
Sonata Glenmark Prescription drugs Ltd? Let the Analyst Information You.
Bored with guessing shares to commerce in every day?
Unicorn Indicators empowers you with highly effective instruments like every day inventory scans for Intraday, Swing & Investing, Market Predictions and way more. Obtain the Unicorn Indicators app right now and take management of your investments!
